Navigation Links
Bevacizumab offers no benefit for newly diagnosed glioblastoma, MD Anderson-led study finds
Date:2/19/2014

HOUSTON The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to a study led by researchers at The University of Texas MD Anderson Cancer Center.

The study appears in the New England Journal of Medicine, and was first presented on the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting by Mark Gilbert, M.D., professor in MD Anderson's Department of Neuro-Oncology.

Glioblastoma is both the most common and lethal form of brain cancer. More than 12,000 people will be diagnosed with the disease in 2013, with an average survival rate of less than 18 months, said Gilbert.

Bevacizumab works as a monoclonal antibody against VEGF-A, which is produced by glioblastoma to stimulate blood vessel growth. The angiogenesis inhibitor first showed promise in glioblastoma as clinicians reported positive results treating the disease under approved compassionate use.

Numerous institutional studies then found similar results: a 35-40 percent objective response rate, or tumor shrinkage, of more than 50 percent, and a six-month PFS rate in the mid-30 percent, said Gilbert, the study's senior author. With those findings, in May 2009, the FDA granted an accelerated registration of bevacizumab in the second-line setting.

However, before this trial, no randomized, double-blind studies with the drug in glioblastoma had been conducted.

"Obviously, glioblastoma is a cancer with too few effective therapies," said Gilbert, who also holds the Blanche Bender Professorship in Cancer Research. "When we launched this study, those in the field of brain cancer both the scientific and patient communities -- were excited. Bevacizumab recently received approval in the second-line (recurrent disease) setting, and we knew some physicians were already giving
'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Bevacizumab (Avastin) fails to improve survival for newly diagnosed glioblastoma patients
2. Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer promising
3. Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)
4. Brain cancer survival improved following FDA approval of bevacizumab, Mayo study finds
5. Test helps target glioblastoma patients most likely to benefit from bevacizumab
6. Bevacizumab offers no benefit for newly diagnosed glioblastoma, M.D. Anderson-led study finds
7. Study finds glioblastoma patients treated with bevacizumab experience reduced cognitive function and quality of life
8. Time to tumor growth helps predict survival benefit of Bevacizumab for patients with metastatic colorectal cancer
9. Innovating for the Global South: New book offers practical insights
10. Fruit fly microRNA research at Rutgers-Camden offers clues to aging process
11. NIH study offers insight into why cancer incidence increases with age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- For patients ... is enough to trigger airway inflammation for at least ... just what you smell, but also what you think ... Monell Chemical Senses Center in Philadelphia, said in a ... about scents and fragrances. When we expect that an ...
(Date:7/30/2014)... jockeying for supremacy within a cancerous tumor, the most ... fastest, researchers at Dana-Farber Cancer Institute report in a ... journal Nature . The findings have important ... the study authors explained: Doctors need to ascertain which ... metastasis and select drugs that target the critical genes ...
(Date:7/30/2014)... 2014 On July 29, 2014, Freedom ... Institute of Public Health, Gandhinagar released a new report ... II: The Way Forward .” The report was released ... and Practices to Improve Nutrition Security in New Delhi, ... the Green Revolution" and chair of the Coalition ...
(Date:7/30/2014)... 2014 Shabaikai is an ambitious historical ... the Pomo Indians located on the shores of Russian ... Shabaikai, meaning ‘crooked snake’. Clarkson takes the reader into ... violence of prohibition and organized crime, providing a glimpse ... the most powerful men in the world convene the ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 With the recent ... Ground Zero, the Ground Zero Museum Workshop in the Meatpacking ... bookings. Says the Museum Workshop's Carole Barnes, "We have had ... all the major travel sites who sell us so tourists ... crystal clear as to what we do and what the ...
Breaking Medicine News(10 mins):Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 4Health News:Bill E. Clarkson Releases Debut Fact-Based Novel, Shabaikai 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 3Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 4Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 5
... the second day of Sedation Dentistry Safety Week, the spotlight ... team members throughout the United States who help ensure that ... comfortable and anxiety-free. "Safety is very much an all-team responsibility," ... and one of the world,s leading sedation dentistry educators. ...
... the reader,s choice award for Westlake village and East Ventura County in ... caring local business represented in the newspaper. , ... Westlake Village, CA ... Khanna the reader,s choice award for Westlake village and East Ventura ...
... Diamond Mothers Day Card for Breast Cancer Campaign,Hallmark Cards ... designed by Strictly Come Dancing host, Tess Daly, to support its ... donate £1/4 million to two breast cancer charities. , ... ...
... given financial incentives to improve the quality of ... of changes important to advancing quality, according to ... adopted by medical groups include speeding up adoption ... more closely tracking the improvement of physician performance ...
... Invention Machine , a leading provider of ... by Blue Highway LLC to help transform ... in medical diagnostics. A Welch Allyn company, ... software to accelerate and sustain product innovation, deliver ...
... MOUNTAIN VIEW, Calif., March 9 Alexza Pharmaceuticals, Inc. ... corporate presentation will be webcast live during the Cowen ... 17, 2008 at 4:40 p.m. Eastern Time. The ... Place. To access the live presentation via the ...
Cached Medicine News:Health News:Sedation Dentistry Safety Week Spotlights the Important Role of Dental Team Members 2Health News:Sedation Dentistry Safety Week Spotlights the Important Role of Dental Team Members 3Health News:Ventura County Star Newspaper Honors Khanna Institute 2Health News:Tess Daly Supports Hallmark's Breast Cancer Campaign 2Health News:Tess Daly Supports Hallmark's Breast Cancer Campaign 3Health News:Study finds pay for performance stimulates changes in medical practice 2Health News:Study finds pay for performance stimulates changes in medical practice 3Health News:Blue Highway Selects Invention Machine Goldfire to Fuel Product Pipeline and Sustain Breakthrough Innovation 2Health News:Blue Highway Selects Invention Machine Goldfire to Fuel Product Pipeline and Sustain Breakthrough Innovation 3Health News:Alexza's Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference 2Health News:Alexza's Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference 3
(Date:7/30/2014)... PITTSBURGH , July 30, 2014   ... Markets Groups Inc.: OTC Pink: UPZS), a Delaware ... a distribution agreement with Larasan Pharmaceutical Corporation ("Larasan"), a ... products.  According to the agreement, US-based Larasan will ... gourmet 6" frozen pizza through Larasan,s vast distribution ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
(Date:7/30/2014)... -- Packaging Coordinators, Inc. (PCI) is pleased to announce it ... Services Limited (Penn Pharma). Penn Pharma is headquartered in Tredegar, ... United Kingdom and operates regional offices in ... Tokyo , Japan. Penn Pharma offers both drug ... form manufacturing, as well as Clinical Packaging, Labeling, and ...
Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
... imaging,(BSGI) is effective in the detection of cancers not ... study presented today at the annual meeting of,the Radiological ... "BSGI can identify the most difficult ... F. Brem, M.D., professor of,radiology and director of the ...
... Horizon Therapeutics, Inc., a,privately held biopharmaceutical ... 3 trials evaluating its lead investigational ... HZT-501, a novel, proprietary fixed-dose,combination product ... significant reduction in the incidence of ...
Cached Medicine Technology:New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4
... The Finnpipette BioControl multichannel ... features as the single ... handle fits all seven ... channel tip cone modules. ...
... The Finnpipette Digital Multichannel, ... even lighter work of routine ... all these advanced features: Soft-touch ... micro volume pipetting (0.5-10ul models), ...
... operate in a wide variety of applications. • ... manifold can be freely rotated against the handle ... at an optimum angle towards the microtiter plate. ... use of most common pipette tips, and provides ...
... Digital Multichannel, with it's streamlined ... of routine laboratory tasks. The ... features: Soft-touch tip ejection, Super ... (0.5-10ul models), Entire pipette autoclavable, ...
Medicine Products: